within the intracellular glycosylation machinery, to suspension CHO cells developed to secrete suitable amounts (200 μg/ml) of Cetuximab as a model glycoprotein. The presented Golgi engineering project aims in the extension of the intrinsic glycosylation repertoire enabling CHO cells to produce new human-type glycosylation motifs as indicated in Figure 1A : (i) GalNAcβ1,4GlcNAc-R (LacdiNAc, LDN),(ii) GlcNAc in β1,4 linkage to central mannose residue (bisecting GlcNAc, bGN), (iii) Galβ1,4(Fucα1,3)GlcNAc-R (Lewis X , Le X ) and (iv) NeuAcα2,3Galβ1,4 (Fucα1,3)GlcNAc-R (Sialyl-LewisX, sLe X ). To assemble (ii) and (iv), we coexpress GnT3 and FT7. As shown earlier, the latter enzyme catalyzes fucosylation exclusively of (iv). Therefore, we included in our study a variant of FT6 that is targeted to the early Golgi compartment with the aim to additionally generate structure (iii) [6, 7] . The uncommon LDN motif (i) which is e.g. detected on lutropin is assembled by human B4GalNT3 [8, 9] . We analyze oligosaccharides released from the products of genetically engineered CHO cells based on the resolution of single glycosylation sites of VH-and CH2-glycopeptides by quantitative NP-HPLC-FLD and use our comprehensive oligosaccharide standard library to identify novel oligosaccharide motifs.
Experimental approach
Cloning of human glycosyltransferases and engineering of VAR FT6 [7] as well as construction of pGET expression plasmids encoding either the heavy and light chain of Cetuximab or the glycosyltransferase cDNAs was done acc. to standard DNA technologies. A stable clone with Cetuximab titers of 200 μg/ml and doubling times * Correspondence: reinl@glycothera.de 1 Dept. Cell Engineering, Feodor-Lynen-Str. 35, 30625 Hannover, Germany Full list of author information is available at the end of the article of 25 hours was selected after transfection of pGETCetuximab in CHO cells. This clone was either mockor co-transfected with pGET plasmids encoding the indicated glycosyltransferases. After shake flask subcultivation for 72 h Cetuximab was purified from supernatants, digested and applied to RP-HPLC peptide mapping. CH2-and VH-domain glycopeptides were separated and oligosaccharides were enzymatically released. After 2-AB labeling, the isolated oligosaccharides were subjected to quantitative NP-HPLC-FLD and ESI-TOF-MS and MS/MS analysis. Oligosaccharide structures were unambiguously identified in comparison to GlycoThera's reference standard oligosaccharide library.
Results and discussion
n combination with our site specific and quantitative micro glycan structure analysis we provide a modular system (GET) for the customized assembly of novel CHO unrelated oligosaccharide motifs. As exemplified for VH-domain, the NP-HPLC-FLD elution profiles of 2-AB labeled oligosaccharides after heterologous coexpression of Cetuximab and the indicated glycosyltransferases are shown in Figure 1B . Quantitative results of all oligosaccharide structures are given in Figure 2 . The Mock-transfected control approach reveals the intrinsic glycosylation repertoire of our stable CHO cell clone. Cetuximab is decorated with agalactosylated (35,5%), mono-(50,0%) and di-galactosylated (10,1%) diantennary complex-type N-glycans containing proximal α1,6-linked fucose at the CH2-domain. VH-domain N-glycans consist of neutral (13,8%), mono-(50,3%) and di-sialylated (35,8%) oligosaccharide structures. Whereas N-glycans from the market product Erbitux ® produced in SP2/0 cells are extensively decorated with Galα1,3Gal and NeuGc (data not shown), those allergenic structures are not detected in Cetuximab N-glycans from our CHO cell clone.
The heterologous co-expression of wildtype B4GalNT3, GnT3 and FT7 and genetically modified FT6 results in the formation of the uncommon LacdiNAc motif (ca. 40%), the Lewis X and di-Lewis X structures (ca. 50%) and Sialyl-Lewis X (ca. 15%) almost exclusively on oligosaccharides from the VH-domain. Relevant modification of both VH-domain (ca. 40%) and CH2-domain glycans (ca. 30%) is only achieved by GnT3 catalyzed attachment of bisecting GlcNAc. In addition, glycosyltransferase co-expression leads to charge state reduction of oligosaccharides by depletion of suitable acceptors for endogenous sialyltransferases. The strongest reduction in the content of neuraminic acid at VH-domain was observed by co-expression of VAR FT6 (ca. 55% reduction) and WT B4GalNT3 (ca. 50% reduction).
As a conclusion, Golgi engineering endows CHO cells to assemble significant amounts of LacdiNAc, bisecting GlcNAc, Lewis X and Sialyl-Lewis X to Cetuximab N-glycans ( Figure 1B and Figure 2) . Therefore, our glycosylation engineering strategy provides a tool to produce tailored N-glycosylation variants with defined structural motifs. As demonstrated, the tailored addition of bisecting GlcNAc to CH2-domain N-glycans increases ADCC of an αCD20 therapeutic mAB [10] . We therefore assume that the presented structural motifs exhibit novel therapeutic properties (ADCC, CDC, tissue specificity, serum half-life). Our strategy represents a relevant basis for the development of biotherapeutics and biobetters with potentially improved pharmacokinetics, pharmacodynamics, safety properties and in vivo therapeutic efficacy. 
